<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688127</url>
  </required_header>
  <id_info>
    <org_study_id>r22wa2xt</org_study_id>
    <nct_id>NCT02688127</nct_id>
  </id_info>
  <brief_title>Efficacy of Tranexamic Acid In Reducing Blood Loss During Cesarean Section Because Of Placenta Previa</brief_title>
  <official_title>Efficacy of Tranexamic Acid In Reducing Blood Loss Among Pregnant Women During Cesarean Section Because Of Placenta Previa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate role of tranexamic acid in reducing blood loss among pregnant women
      undergoing cesarean section because of placenta previa .Half of participants will receive
      tranexamia acid drug While the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic Acid used in the field of obstetrics to decrease blood loss during and after
      cesarean section .

      Tranexamic Acid is an antifibrinolytic agent which cause reversible and competitive blockade
      of the lysine binding sites in plasminogen molecules . It is a synthetic analog of amino acid
      lysine and its action is to reduce blood loss
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Actual blood loss in each group</measure>
    <time_frame>6hour after operation</time_frame>
    <description>observational</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in haemoglobin before operation and 24 hours after operation</measure>
    <time_frame>24 hours</time_frame>
    <description>observational</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Postpartum Haemorrage Sever Bleeding After Delivery</condition>
  <arm_group>
    <arm_group_label>tranexamic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the control group will receive 500 cc of ringer lactate 20 minute before cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>tranexamic acid or placebo are given before cesarean section in patient with placenta previa</description>
    <arm_group_label>tranexamic acid group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>cyclo kapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 -38 Body mass index &lt;30 , Diagnosis of placenta previa

        Exclusion Criteria:

          -  patient with bleeding disorder , hepatic and renal disease. contraindication to
             tranexamic acid as allergy , hypersensitivity to tranexamic acid and known
             thromboembolic event during pregnancy .

        other causes ofantepartum haemorrhage eg :accidental haemorrhage, rupture uterus.

        type 1,2 of placenta previa anterior type 3,4 of placenta previa posterior causes of
        overdistended uterus like :multiple pregnancy, polyhydraminos
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>shaimaa- sayed</investigator_full_name>
    <investigator_title>Director , Clinical Research</investigator_title>
  </responsible_party>
  <keyword>obstetric bleeding placenta previa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

